Peter Blume-Jensen - 01 Mar 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: President and CEO, Director
Issuer ticker: ACRV
Reported as of: 01 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:15:29 UTC
Prior SEC filing: 24 Feb 2026
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen

Key filing fact

Peter Blume-Jensen filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 03 Mar 2026.

Key facts

This page summarizes Peter Blume-Jensen's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 16:15.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001950499 Primary reporting owner

Blume-Jensen Peter

Relationship: President and CEO, Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
Signature date: 03 Mar 2026

CIK 0001950501

Masson Kristina

Relationship: EVP - Business Operations, Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson
Signature date: 03 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +417,210
Change %
Price: $0.000000
Shares after: 417,210
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 417,210
Exercise price: $1.51
Footnotes: F1, F2

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +185,495
Change %
Price: $0.000000
Shares after: 185,495
Date: 01 Mar 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 185,495
Exercise price: $1.51
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Footnote F2

These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Footnote F3

These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.